AGM 2026 presentation
Logotype for XRF Scientific Limited

XRF Scientific (XRF) AGM 2026 presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for XRF Scientific Limited

AGM 2026 presentation summary

18 Oct, 2026

Technology and products

  • Sample preparation and analysis technologies serve mining, manufacturing, commercial labs, research and education; applications include iron ore, gold, nickel, copper, cement, metals and glass, using XRF, ICP, fire assay and photon assay.

  • Orbis crushers reduce 110 mm drill-core samples to 2 mm in one pass, with automated splitting, loader options and a design for continuous use in harsh mining conditions.

  • Lab products include platinum labware, X-ray flux and fusion machines, plus recycling used platinum products into new items.

  • XRTGA supports analysis of moisture, volatiles, ash, fixed carbon and loss on ignition; applications include mining, construction materials, food, plastics and agriculture.

  • CGA elemental analysis covers carbon, sulphur, oxygen, nitrogen and hydrogen for quality control across metals, alloys, welding, magnetic materials and additive manufacturing.

FY26 highlights

  • Strong mining and industrial demand, international sales growth in developing markets, particularly Asia, and continued growth in Orbis crusher sales.

  • Acquired the CGA Elemental Analysis Instrument business from Bruker AXS SE on 23 April 2026 for upfront consideration of US$4m; opened offices in India and the US.

  • FY26 revenue rose 8% YoY to $64.4m; adjusted NPBT increased 10% to $16.1m.

  • NPAT increased 1% to $10.5m after acquisition and international-office startup costs; effective tax rate rose to 32% from 29%.

  • Gross margin was 49.3% vs 48.4% in FY25; fully franked dividend was 4.5 cents per share, and Q4 adjusted PBT reached a record $4.7m on $17.2m revenue.

Balance sheet and cash flow

  • Net cash position was $8.5m at FY26 year-end; cash and cash equivalents were $9.5m vs $12.2m in FY25.

  • CGA acquisition was funded entirely in cash and added $6.2m to intangible assets, $1.0m to inventories and $1.4m to other payables for acquisition earnout liability.

  • Operating cash inflow was $11.4m vs $10.1m in FY25; investing outflow was $8.1m, including $5.6m for the CGA acquisition.

  • Financing cash outflow was $6.0m, including $5.0m paid for the FY25 dividend; cash ended the period at $9.5m.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from XRF Scientific